Levetiractam in the treatment of two children with myoclonic status epilepticus.
Levetiracetam (LEV) is approved as second line treatment for partial onset seizures in adults and children older than four years of age. Recently, an intravenous formulation was developed as an alternative to standard oral medication. We report the successful treatment of two children suffering from myoclonic status epilepticus with intravenous LEV. Intravenous application of LEV was safe and not associated with significant side effects. In conclusion, intravenous application of LEV appears to be a further option in treatment of children with myoclonic status epilepticus.
Haberlandt
E
E
Department of Pediatrics, Division of Neuropediatrics and Inherited Metabolic Disorders, Medical University Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria. edda.haberlandt@uki.at
Sigl
S Baumgartner
SB
Scholl-Buergi
S
S
Karall
D
D
Rauchenzauner
M
M
Rostásy
K
K
D000927:Anticonvulsants / Q000627:therapeutic use*; D002648:Child; D004569:Electroencephalography; D006801:Humans; D007223:Infant; D000077287:Levetiracetam; D008297:Male; D010889:Piracetam / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013226:Status Epilepticus / Q000188:drug therapy* / Q000503:physiopathology
D000927:Anticonvulsants; D000077287:Levetiracetam; D010889:Piracetam